key: cord-0990124-n1rw9cee
authors: Li, Zexu; Yao, Yingjia; Cheng, Xiaolong; Li, Wei; Fei, Teng
title: An in silico drug repositioning workflow for host-based antivirals
date: 2021-07-07
journal: STAR Protoc
DOI: 10.1016/j.xpro.2021.100653
sha: 11876d27cb0ce95637a0f57615fc9889a812ef12
doc_id: 990124
cord_uid: n1rw9cee

Drug repositioning represents a cost- and time-efficient strategy for drug development. Artificial intelligence-based algorithms have been applied in drug repositioning by predicting drug-target interactions in an efficient and high throughput manner. Here, we present a workflow of in silico drug repositioning for host-based antivirals using specially defined targets, a refined list of drug candidates, and an easily implemented computational framework. The workflow described here can also apply to more general purposes, especially when given a user-defined druggable target gene set. For complete details on the use and execution of this protocol, please refer to Li et al. (2021).

Drug repositioning represents a cost-and time-efficient strategy for drug development. Artificial intelligence-based algorithms have been applied in drug repositioning by predicting drug-target interactions in an efficient and high throughput manner. Here, we present a workflow of in silico drug repositioning for host-based antivirals using specially defined targets, a refined list of drug candidates, and an easily implemented computational framework. The workflow described here can also apply to more general purposes, especially when given a user-defined druggable target gene set. For complete details on the use and execution of this protocol, please refer to Li et al. (2021) .

Overview Artificial intelligence-based algorithms have been applied in drug repositioning as well as other relevant fields (Hao et al., 2016; Pushpakom et al., 2019; Tanoli et al., 2021; Wang et al., 2020; Yang et al., 2020; Zhou et al., 2020) . This protocol below describes the specific steps of in silico drug repositioning for antivirals against Coronaviridae viral families including SARS-CoV-2 (severe acute respiratory syndrome coronavirus 2), SARS-CoV (severe acute respiratory syndrome coronavirus) and MERS-CoV (Middle East respiratory syndrome coronavirus) using Coronaviridae-specific host dependency gene set, refined drug candidate list covering 2457 marketed drugs and 1062 natural compounds, and DeepCPI algorithm for drug-target interaction (DTI) prediction. Moreover, this workflow can be extended for broader drug repositioning purposes, given a user-defined target gene set, a custom list of candidate drug chemicals and implementation of more DTI prediction algorithms.

For specific drug repurposing against Coronaviridae family viruses, we should firstly define the proper gene set for candidate drugs to target. In addition to limited number of virus-specific genes, host dependency genes (HDGs) with functional implications whose loss-of-function renders host resistance to specific viral infection may serve as an ideal target gene pool for inhibitory drugs to exert antiviral effect. Public datasets derived from functional genetic screens using techniques such as gene-trap, RNA interference (RNAi) and clustered regularly interspaced palindromic repeats (CRISPR) have provided a wealth of resource about virus-specific HDGs. We have collected Coronaviridae-specific HDGs in our previous study and use them as target gene set in this protocol. HDGs for a broader range of RNA viruses can also be found in Li et al., 2021 . For the interrogated drug candidates, we build a chemical cohort by collecting 2457 Food and Drug Administration (FDA) approved drugs (Database: DrugBank, version 5.1.7, released 2020-07-02; https://www. drugbank.ca) and 1062 selected natural compounds embedded in herbs of traditional Chinese medicine with favorable druggability . This refined drug candidate list does not include experimental and investigational chemicals. Since FDA approved drugs and herbs of traditional Chinese medicine have already been applied in humans, this refined cohort may represent the safest drug candidates to be readily tested for clinical trials. Precise and efficient DTI prediction stands in a central position for successful drug repositioning. Multiple artificial intelligence-based algorithms have been developed to predict DTI between multiple drugs and targets. In this protocol, we employ DeepCPI, a computational framework using feature-embedding and deep learning, for DTI prediction (Wan et al., 2019) . Compared to other pipelines, DeepCPI is quite computationally efficient which can be run even by a personal computer while maintaining decent predicting power (For example, in the current protocol, DeepCPI can be run on the MacBook Pro with 8 GB of memory to predict 405,405 hypothetical DTI pairs in about 1 h). Each drug-target pair is scored by DeepCPI for their potential interaction, and repurposed drug candidates are then prioritized according to their targeting range (the number of predicted targets) and strength for interrogated targets (targeting potential reflected by DTI score). For the top ranked drug candidates, molecular docking analysis is performed to take a closer examination for the binding interface and free energy of potential drug-target interaction. The workflow generates a ranked list of potential repurposed drug candidates against Coronaviridae viruses that are ready for in-depth experimental and clinical evaluation.

Timing: $1 day A personal computer with Linux-or Unix-based operating system is required to execute this protocol. The prerequisite software (in key resources table) can be downloaded from the corresponding websites. The accompanying user manuals provide detailed information about their functions and uses. 2. Filter the collected data to pinpoint HDGs. If a host gene or its encoding protein is shown only to physically interact with viral proteins or regulated by viral genes but without functional implication on viral life cycle upon gene's lossof-function, the gene is not classified as a HDG. A gene is defined as a HDG only when it meets any of the following criteria: a. Its loss-of-function impedes or reduces viral infection or activity by experimental evidence in non-screen studies. b. It has been clearly classified into HDG group in screen studies. c. When HDG group is not specified in screen studies, arbitrarily take the top $5% of all the interrogated genes in the positive selection list as HDGs with a custom log-fold change cutoff in CRISPR knockout or RNAi screens. For example, in a typical result output generated by MAGeCK (Li et al., 2015; Li et al., 2014) analytic pipeline for CRISPR screens, genes can be ranked according to their negative or positive selection trend by jointly considering the logfold change and statistical significance of their corresponding guide RNAs. HDGs can be arbitrarily defined as the top $5% of all the genes with a log-fold change of 1.0 (loose cutoff) or 2.0 (stringent cutoff).

3. Define high confidence HDG gene set for Coronaviridae family viruses.

As there are several independent studies and datasets for HDG identification against Coronaviridae family viruses, we only take a subset of HDGs that occurs more than once among different datasets as high confidence HDGs for further analysis. A total of 165 high confidence HDGs are defined for Coronaviridae viruses ( Figure 1A ). After that, prepare a HDG file in the structure of ''gene symbol + amino acid sequence'' ( Figure 1B , Supplemental File S1). 

Note: In addition to PubMed, public integrated database such as ''CRISP-view'' (http:// crispview.weililab.org/) can also be used to search high throughput genetic screen studies or datasets (Cui et al., 2021) . In addition, virus-specific HDGs for 10 families and 29 species of RNA viruses can be downloaded from .

Define the cohort of candidate drugs or chemicals for repurposing (Ru et al., 2014) . b. Filter the pool of 1455 natural compounds for better druggability by requiring each candidate passing the criteria of oral bioavailability (OB) R 30.0%, drug-likeness (DL) R 0.18 and bloodbrain barrier (BBB) R -0.30. Finally, 1062 selected natural compounds with InChI information are kept for the downstream DTI analysis. c. Extract the compound ID and InChI, and save them as separate files in the structure of ''compound ID + InChI'' (Supplemental File S1).

Note: The above drug cohort information used in this protocol can be found in Table S1 .

Timing: $2 h (variable)

DeepCPI requires two layers of information for DTI prediction: ''the InChl information of drugs'' and ''the amino acid sequence of target gene-encoding proteins''.

6. Prepare a txt file (e.g., ''Drugbank_Approved.txt'' or ''TCM_selected.txt'') containing the InChl information for each drug ( Figure 1B , Supplemental File S1). 7. Prepare a txt file (e.g., ''Coronaviridae_HDGs.txt'') containing the amino acid sequence for each target protein ( Figure 1B , Supplemental File S1). The amino acid sequences are extracted from UniProt database (https://www.uniprot.org/). 8. Save the two files (''Coronaviridae_HDGs.txt'' and ''Drugbank_Approved.txt'') under the same directory. 9. Open Terminal. 10. Change directory to where the files (''Coronaviridae_HDGs.txt '' and ''Drugbank_Approved.txt'') are located by typing ''cd /your/working/path''. 11. Run python script ''DrugTargtPairGenerator.py'' by typing ''python DrugTargtPairGenerator.py -f1 Coronaviridae_HDGs.txt -f2 Drugbank_Approved.txt'' to generate a merged txt file (e.g., ''Drug_Target_Pair.txt'') with each possible drug-target pair ( Figure 1C ). Optional: When more DTI prediction algorithms are applied to alleviate the bias of each algorithm and improve the prediction precision, each method generates a prediction score for the same drug-target pair. However, the score distribution pattern is usually different between different methods. To make these DTI scores comparable, a z-score based normalization is recommended as exemplified in the following steps to standardize DeepCPI score. DTI scores derived from other prediction algorithms can be normalized in the similar manner. j. Open and run R script ''ZscoreNormalization.Rmd'' to generate z-score matrices Z CPI named ''z_Prediction_results.txt'', where, m is mean value of the original scores and s is standard deviation of the original scores: 

Timing: $10 min

Repurposed drug candidates are ranked primarily according to their targeting range (the number of target) and targeting strength (the interaction potential of target).

13. Prioritize the drug candidates using P_score that only considers the HDG target-associated DTIs. P_score is calculated for each drug candidate by the following formula, where x CPI sig represents filtered DeepCPI score for each drug-target pair and k refers to the length of target list.

k; x CPI sig˛TCPI sig a. Open the file ''Prediction_results.matrix.filtered.txt'' using Excel sheet. Drugs are listed in rows and targets are listed in columns. b. For each drug, calculate P_score using the above formula (AVERAGE function). The higher of P_score, the better the corresponding drug is prioritized. c. The drug candidates can be ranked according to their P_score.

Optional: If using normalized z-score, calculate P_score for each drug candidate corresponding to each DTI prediction method by the following formula exemplified by DeepCPI, where z CPI sig represents filtered DeepCPI score for each drug-target pair and k refers to the length of target list. Drug candidates can be ranked by integrative consideration of multiple P_score derived from each DTI prediction methods. To further examine the potential binding interface and free energy between top ranked drugs and their predicted target proteins, molecular docking analysis can be performed. Using Baricitinib (one of the top ranked repurposed drugs against Coronaviridae viruses) and its predicted target DYRK1A as an example, molecular docking analysis is performed as in the following steps. The docking parameters may vary depending on the interrogated drug/target pair.

e. Run the ''AutoGrid'' and ''AutoDock'' module with ''dock.gpf'' and ''dock.dpf'' file, respectively. A ''dock.dlg'' file is then generated. f. Open the ''dock.dlg'' file and protein file (''protein.pdbqt''). g. Show the interactions between ligand and protein ( Figure 3F ). h. Analyze the conformations of ligand and click this button ( ) ( Figure 3G ). The DashBoard shows the binding energy under different ligand conformations with the lowest binding energy of -8.07 kcal/mol for potential interaction between Baricitinib and DYRK1A A chain. i. Output the complex interactions, and save as ''result.pdbqt'' formatted file. Note: Other molecular docking software can also be utilized. The binding interface and free energy may differ when using different molecular docking platforms. 

Note: If there is no structure of interrogated target protein available in PDB website, protein structure prediction by homology modeling may be performed. If there is only apo-structure available where the target protein is not in complex with drugs or small molecules, binding pocket prediction or blind docking can be performed with molecular docking software.

Optional: If a deeper computational investigation on the binding-function relationship is needed, molecular dynamics (MD) simulation can be performed as elaborated in other literatures (Maximova et al., 2016; Mei et al., 2021; Yang et al., 2020) .

In this protocol, we describe an in silico drug repositioning workflow to identify potential antiviral drugs against Coronaviridae viruses using HDGs as drug targets. A complete table listing the predicted DTI for each drug-target pair is generated, and a ranked list of the repurposed drug candidates is provided (Table S2 ). If there are positive control drugs with definite DTIs in other scenarios, they are expected to be present among the top positions of the ranked list. The binding details between top predicted drugs and targets are illustrated by molecular docking analysis. These results may expedite the drug development for infectious diseases caused by Coronaviridae viruses such as COVID-19. This strategy should be helpful to repurpose ''old drug'' for novel antiviral uses by facilitating the selection of lead compound for in-depth experimental and clinical evaluation.

There are several limitations for this protocol. Firstly, the target gene set of Coronaviridae-specific HDGs may not be complete and the strength variation of perturbation impact between different HDGs is ignored. Secondly, only one DTI prediction algorithm (DeepCPI) is illustrated here and it is highly recommended to incorporate more independent algorithms to increase the precision and reduce the bias for DTI prediction. Thirdly, this protocol does not include the validation steps. The top ranked repurposed drug candidate should be readily selected and experimentally validated by performing in vitro assays for their cytotoxicity, antiviral activity and physical drug-target interaction before proceeding to more advanced evaluations.

The software and algorithms used in this protocol do not run through properly (Before you begin-Software setup and installation).

Double check the computer settings, make sure the downloaded versions of the software or algorithms are correct, and install them according to their manuals. Use the test data or files provided in this study to evaluate whether the software and algorithms are working properly.

Only a limited number of HDGs can be collected for specific type of virus (steps 1-3).

Potential solution Insufficient number of target genes may decrease the probability and precision of drug repositioning due to low coverage of true HDGs. We recommend to expand the HDGs by additionally considering the HDG data from closely related viruses, for example, within the same viral family rather than only restricted to certain species of viruses.

DeepCPI is successfully installed and go through using the test data embedded in DeepCPI folder, however, it fails to generate results using user-provided data (steps 6-12).

Make sure to execute the program under the home directory of DeepCPI folder, double check the format of the input file, and remove any delimiter in the InChI value that may change the data structure.

It is difficult to determine the position of the grid box for the protein during molecular docking (step 16).

We recommend to try the following steps: firstly, refer to the literatures to identify potential active pocket of the protein; secondly, use ''blind docking'' or ''binding pocket prediction'' approach by AutoDock software.

The positive control drugs (if there are) are not in the top positions among the prioritized rank list of repurposed drugs (Expected Outcomes).

Carefully select the target gene set, make sure the positive control drugs are within the interrogated drug cohort, and/or apply multiple DTI prediction algorithms for drug repositioning.

Lead contact Further information and requests for resources and reagents should be directed to and will be fulfilled by the lead contact, Teng Fei (feiteng@mail.neu.edu.cn).

This study did not generate new unique reagents.

This published article includes all datasets generated or analyzed during this study. The Python and R scripts can be found at the GitHub repository for this protocol (https://github.com/zexuneu/ computational-framework-of-host-based-drug-repositioning).

Supplemental information can be found online at https://doi.org/10.1016/j.xpro.2021.100653. 

Download the chemical structure file for Baricitinib (PubChem CID: 44205240) from Pub-Chem website

Open a PyMOL software browser and input the ligand file ''Baricitinib.SDF''. c. Export and save as

The red chemical bond means un-rotatable, the green chemical bond means rotatable. f. Output and save as ''ligand.pdbqt

Prepare the protein receptor

Open a PyMOL software browser to input the file ''6SIE.pdb''. c. Remove waters (Figure 2D) and add polar hydrogens (Figure 2E)

Choose the primary ligand of DYRK1A at the 321st amino acid position of A chain, and remove the pre-embedded ligand

Delete the other chains (B, C, and D chains of DYRK1A in 6SIE.pdb) and solvents of the protein (Figure 2G)

Save as ''protein.pdb'' formatted file. g. Open the AutoDock software and input the ''protein.pdb'' file. h. Set the atoms using

Compute the Gasteiger charges for protein molecules (Figure 3B)

Export and save as ''protein.pdbqt'' formatted file (Figure 3C)

Grid'' module and input the ''protein.pdbqt'' file. b. Set map types and input the ''ligand.pdbqt'' file. c. Open ''Grid Box'' module to set the position of grid box

Save as ''dock.gpf'' formatted file

Analyze the grid docking. a. Choose the ''Docking'' module, and input the protein and ligand files (''protein.pdbqt'' and ''ligand

Genetic Algorithm'' module. c. Click ''Docking->Docking Parameters'' and use the default settings. d. Output the Lamarckian GA result and save as ''dock.dpf

CRISP-view: a database of functional genetic screens spanning multiple phenotypes

ACFIS: a web server for fragment-based drug discovery

Quality control, modeling, and visualization of CRISPR screens with MAGeCK-VISPR

A computational framework of host-based drug repositioning for broad-spectrum antivirals against RNA viruses

Principles and overview of sampling methods for modeling macromolecular structure and dynamics

Protocol for hit-to-lead optimization of compounds by auto in silico ligand directing evolution (AILDE) approach

AutoDock4 and AutoDockTools4: Automated docking with selective receptor flexibility

Drug repurposing: progress, challenges and recommendations

TCMSP: a database of systems pharmacology for drug discovery from herbal medicines

Artificial intelligence, machine learning, and drug repurposing in cancer

DeepCPI: A deep learning-based framework for large-scale in silico drug screening

Graph attention convolutional neural network model for chemical poisoning of honey bees' prediction

DrugBank 5.0: a major update to the DrugBank database

LARMD: integration of bioinformatic resources to profile ligand-driven protein dynamics with a case on the activation of estrogen receptor

Artificial intelligence in COVID-19 drug repurposing